The AHA and other plaintiffs late Friday asked a federal district judge to set a firm June deadline for the Department of Health and Human Services to propose remedies to the nearly 30 percent cuts to Medicare payments affecting certain hospitals that participate in the 340B Drug Pricing Program. The judge last week had set an Aug. 5 deadline for the remedies.
 
In the filing, the plaintiffs said “it is important that the Court require HHS to propose its remedy by the end of June 2019 or shortly thereafter, since unless there is a Court order on the remedy in this case this summer, Defendants may issue a 2020 OPPS [outpatient prospective payment system] rule reducing reimbursements for 340B drugs by nearly 30 percent in violation of law, just as they did in 2018 and 2019.” While the final OPPS rule generally is issued by the Centers for Medicare & Medicaid Services in November, the agency typically issues its proposal in late July. 
 
A federal district court judge last week said HHS would get "first crack at crafting appropriate remedial measures" to the cuts, and also held that, like the 2018 cuts, the 2019 cuts to 340B hospitals were unlawful.
 

Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…
Headline
The AHA today voiced support () for the 340B Rebate Model Delay Act (H.R. 10770)in a letter to the bill’s House sponsors. The bipartisan bill would pause the…
Headline
The AHA, the Maine Hospital Association and four safety-net hospitals Oct. 9 filed a lawsuit in the U.S. District Court for the District of Maine challenging…
Headline
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a…
Headline
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the…